Banyu Pharmaceutical Co. Ltd

Taiho Pharmaceutical Company Limited

Msd K.k.

Mds K.k.

Banyu Pharmaceutical Coaltd

Morihiro Mitsuya

Yoshikazu Iwasawa

Katsumasa Nonoshita

Takashi Nomoto

Masahiro Hayashi

Yasuhiro Sasaki

Jun Shibata

Teruyuki Nishimura

Makoto Bamba

Jun-ichi Eiki

Yasufumi Nagata

Tetsuya Sugimoto

Yoshiaki Iida

Masayuki Nakamura

Hiroyoshi Yamanaka

Fumiko Sakai

Hitomi Watanabe

Yoshiyuki Sato

Takafumi Harada

Hiroshi Sootome

Hidekazu Takahashi

Norio Masuko

Mikako Kawamura

Hideya Komatani

Kaori Kamijo

Kazuaki Shibata

Takashi Hashihayata

Toshio Kamei

Toshiaki Mase

Yoshimi Tsuchiya

Toshihiko Satoh

Fuyuki Yamamoto

Satoshi Sunami

Kazuhito Noguchi

Hideki Kurihara

Keisuke Arakawa

Kensuke Kobayashi

Yoshio Sawasaki

Yu Onozaki

Toshiaki Tsujino

Akiko Watanabe

An object of the present invention is to provide a salt of the compound 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid, useful as an antitumor agent, and crystals thereof which are excellent in solubility, stability, and oral absorption and can be produced in large quantities. The present invention relates to a hydrochloride salt of 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid and crystals of the hydrochloride salt having characteristic peaks at particular diffraction angles in powder X-ray diffraction spectrum.

Salt of substituted piperidine compound

Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-&#x3b3; production in vivo. A compound represented by formula (I) [wherein X represents &#x2014;CH&#x2550;CH&#x2014;, &#x2014;NH&#x2014;, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof. 

Pyrrolo[2,3-d]pyrimidine compound or salt thereof

A novel compound which has an excellent aurora A-selective inhibitory action and is useful as an orally administrable anticancer agent is provided. Also, a novel agent for potentiation of anti-tumor effect of microtubule agonists, which include a taxane anticancer agent, and a combination therapy are provided. A piperidine compound represented by a general formula (I) or a salt thereof: 

Piperidine compound or salt thereof

A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject 

Azaindole derivative

Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where Rto R, m and n have the same meanings as those defined in the description.

The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein Xrepresents a nitrogen atom, sulfur atom, oxygen atom or the like; Rrepresents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; Rand Rare the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

2-pyridinecarboxamide derivatives

The present invention relates to a compound represented by the Formula [I]: Wherein:

Fused imidazole derivative

The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein Rand R, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; Rand R, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRR, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4-to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5-or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5-or 6-membered aromatic heterocyclic group, or the like; and Ris a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

Aminopyrimidine derivatives as PLK1 inhibitors

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein:

Substituted imidazole derivative

The present invention provides a compound having a glucokinase activating action being useful for prevention or treatment of diabetes mellitus, etc. being represented by the formula (I): X is nitrogen atom, etc.; Y is oxygen atom, etc.; Ris an optionally substituted five to six-membered heteroaryl group, etc.; Ris hydrogen atom or fluorine atom; and ring A is a monocyclic or bicyclic heteroaryl group which may have a substituent represented by the formula (II)] or a pharmaceutically acceptable salt thereof.

Substituted quinazoline or pyridopyrimidine derivative

2-pyridine carboxamide derivatives

Substituted piperidine derivatives as muscarinic M.sub.3 receptor

A compound of the formula (I) or its pharmaceutically acceptable salt or ester: ##STR1## wherein each of ##STR2## which are the same or different, is an aryl group or a heteroaromatic ring group; A is a C.sub.3-8 linear saturated or unsaturated aliphatic hydrocarbon group which may have substituent(s) selected from the group consisting of a lower alkyl group, a hydroxyl group, a lower alkoxy group, a carboxyl group, an aryl group and an aralkyl group; Q is a single bond or a group of the formula --CO--O--, --O--CO--, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --OCH.sub.2 --, --SCH.sub.2 --, --CH.sub.2 O-- or --CH.sub.2 S--; each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 which are the same or different, is a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, or an aryl or heteroaromatic ring group which may have substituent(s) selected from the group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group; each of R.sup.5, R.sup.6 and R.sup.7 which are the same or different, is a hydrogen atom or a lower alkyl group; and R.sup.8 is a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group or an aralkyl group, provided that when Q is a single bond, ##STR3## are not simultaneously 4-chlorophenyl groups.

Substituted amic acid derivatives

Growing community of inventors

Tsukuba, Japan

Morihiro Mitsuya